ICANS therapy shows improved outcomes in patients with immune effector cell-related side effects, enhancing treatment benefits.
The analysis includes data from multiple centers, indicating a broad spectrum of outcomes across different settings with varied patient responses.
Assessment of safety outcomes reveals important insights into the risks associated with intrathecal therapy for ICANS treatment, informing clinical practice.
These findings highlight the need for ongoing evaluation of treatment protocols to ensure the best possible patient care and safety.
Terapia Intratecal para el Síndrome de Neurotoxicidad Asociada a Células Efectoras Inmunitarias (ICANS): Un Análisis Multicéntrico Actualizado de Resultados y Seguridad | Synapse